Xencor, Inc. (NASDAQ:XNCR) CEO Sells $1,186,121.46 in Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat sold 49,278 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $24.07, for a total transaction of $1,186,121.46. Following the transaction, the chief executive officer now directly owns 352,615 shares in the company, valued at approximately $8,487,443.05. This represents a 12.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Xencor Stock Up 5.1 %

Xencor stock traded up $1.27 during trading hours on Monday, hitting $26.28. 640,895 shares of the stock traded hands, compared to its average volume of 607,877. Xencor, Inc. has a one year low of $15.31 and a one year high of $26.84. The firm’s 50-day moving average price is $21.47 and its two-hundred day moving average price is $20.37. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.84 billion, a PE ratio of -7.82 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.27. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm’s revenue for the quarter was down 81.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.40) earnings per share. On average, research analysts forecast that Xencor, Inc. will post -3.71 EPS for the current year.

Institutional Trading of Xencor

Hedge funds and other institutional investors have recently modified their holdings of the business. State Board of Administration of Florida Retirement System lifted its position in Xencor by 30.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 21,569 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 4,990 shares during the period. Vanguard Group Inc. increased its stake in shares of Xencor by 3.6% during the first quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock valued at $155,154,000 after purchasing an additional 243,793 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Xencor during the first quarter valued at approximately $206,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Xencor by 4.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 78,425 shares of the biopharmaceutical company’s stock worth $1,733,000 after purchasing an additional 3,210 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Xencor by 9.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after buying an additional 335,881 shares during the last quarter.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on XNCR. Wedbush reaffirmed an “outperform” rating and set a $38.00 price objective on shares of Xencor in a research note on Thursday, November 7th. Royal Bank of Canada increased their target price on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. JPMorgan Chase & Co. lifted their price target on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $34.00 price objective (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.75.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.